Drug Approval | April 02, 2024
AstraZeneca and Daiichi Sankyo’s BLA for Dato-DXd accepted in the US for treatment of breast cancer
Application based on results from the TROPION-Breast01 Phase III trial
Application based on results from the TROPION-Breast01 Phase III trial
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
The surgeons were able to remove the entire breast while preserving the nipple through tiny hidden incisions
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
Subscribe To Our Newsletter & Stay Updated
